CELL INTELLIGENCE · 肿瘤细胞治疗研究

多发性骨髓瘤的治疗决策

Treatment Decisions in Multiple Myeloma.

mezigdomide 降解 Ikaros 减轻 T 细胞功能障碍并提高抗骨髓瘤 T 细胞疗法疗效

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

通过整合优化的 CAR 内结构域和 iNKT 衔接器增强 iNKT 细胞免疫治疗

Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers.

MRD 动态预测多发性骨髓瘤进展并揭示免疫治疗干预的脆弱状态

MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

idecabtagene vicleucel 与复发多发性骨髓瘤无进展生存期相关的内源性 T 细胞表型

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

接受 BiTEs 和 CAR-T 细胞治疗的多发性骨髓瘤感染风险的真实世界证据：一项荟萃分析

Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.

在真实世界实践中，接受 T 细胞重定向治疗的 RRMM 患者中约每 4 例就有 1 例发生严重感染。

标准治疗 ciltacabtagene autoleucel 用于复发/难治性多发性骨髓瘤较早期与较晚期治疗线：一项全国性登记分析

Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry

该分析表明，cilta-cel 用于更早线次治疗可获得深度缓解和较高的 PFS，与 CARTITUDE-4 试验结果一致。

多发性骨髓瘤中的双抗原靶向 T 细胞免疫治疗：规避肿瘤异质性和预防抗原逃逸

Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.

多发性骨髓瘤感染风险增加的免疫生物标志物

Immune biomarkers of increased infection risk in multiple myeloma.

T 细胞动力学、CD8/NK 比值及肿瘤生存特征决定骨髓瘤对 T 细胞双特异性抗体 forimtamig 的应答

T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.